Bulk Pharmaceutical API Sources for CARBAGLU

Bulk Pharmaceutical API Sources for CARBAGLU

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C4375_SIGMA
Amadis Chemical		A804117
TimTec		SBB066020
AKos Consulting & Solutions		AKOS010384789
Molport		MolPort-012-207-739
Mcule		MCULE-6817913906

CARBAGLU Bulk API Sourcing Landscape

Last updated: February 19, 2026

This analysis identifies and characterizes key bulk Active Pharmaceutical Ingredient (API) manufacturers and suppliers for CARBAGLU (carglumic acid). It details sourcing options, regulatory standing, manufacturing capabilities, and potential supply chain risks to inform procurement and investment decisions.

What is CARBAGLU and its Therapeutic Application?

CARBAGLU is a pharmaceutical product containing carglumic acid. Carglumic acid is a synthetic analog of N-acetylglutamate, an allosteric activator of carbamoyl phosphate synthetase I (CPS1). CPS1 is a mitochondrial enzyme crucial for the urea cycle. Inborn errors of the urea cycle, such as ornithine transcarbamylase (OTC) deficiency and N-acetylglutamate synthase (NAGS) deficiency, lead to hyperammonemia, a potentially life-threatening condition characterized by elevated levels of ammonia in the blood. CARBAGLU functions by stimulating CPS1, thereby increasing the flux through the urea cycle and facilitating the detoxification of ammonia. The primary indication for CARBAGLU is the treatment of deficiencies in N-acetylglutamate synthase (NAGS) [1]. It is also used as an adjunctive therapy for acute hyperammonemia in patients with urea cycle disorders (UCDs) [2].

Who are the Primary Manufacturers of CARBAGLU API?

The production of CARBAGLU API (carglumic acid) is concentrated among a limited number of specialized manufacturers. These entities possess the expertise in complex organic synthesis and adhere to stringent Good Manufacturing Practice (GMP) standards required for pharmaceutical ingredient production.

Key API Manufacturers and Suppliers

• Recordati S.p.A.

  • Role: Recordati is the originator company for CARBAGLU and retains significant control over its API supply chain. They are known to manufacture the API internally or through closely managed contract manufacturing organizations (CMOs).
  • Regulatory Standing: Holds multiple marketing authorizations globally and operates under strict regulatory oversight by the FDA, EMA, and other health authorities. Their manufacturing sites are subject to regular inspections.
  • Manufacturing Capabilities: Expertise in complex chiral synthesis and scale-up of pharmaceutical intermediates and APIs. High-capacity production facilities designed to meet global demand.
  • Supply Chain Control: Direct control over API production, ensuring quality and compliance. This offers a high degree of supply chain security but limits direct third-party sourcing options for other entities.

• Specialized Contract Manufacturing Organizations (CMOs)

  • Role: While Recordati maintains primary control, it is plausible that they engage CMOs for specific steps or dedicated production campaigns of carglumic acid. Identifying these specific CMOs is challenging as they are often under strict confidentiality agreements. However, CMOs with capabilities in advanced organic synthesis, particularly those with experience in amino acid derivatives and GMP-compliant production, are potential partners.
  • Regulatory Standing: Any CMO involved in pharmaceutical API manufacturing for approved drugs must operate under cGMP (current Good Manufacturing Practice) and be subject to audits by the drug sponsor and regulatory agencies. Examples of highly regulated CMOs that could potentially be involved include Lonza, Catalent, and Siegfried, though their direct involvement with carglumic acid API has not been publicly disclosed.
  • Manufacturing Capabilities: CMOs offer specialized expertise in process development, scale-up, and commercial manufacturing of complex APIs. Capabilities typically include multi-step organic synthesis, purification, and analytical testing.
  • Supply Chain Impact: The engagement of CMOs provides flexibility and redundancy but also introduces additional layers of management and quality oversight.

Indirect Supply Chain Considerations

• Precursors and Raw Materials: The synthesis of carglumic acid involves specific starting materials and reagents. The availability and reliable sourcing of these precursors are critical. Manufacturers must ensure robust supply chains for key intermediates, such as N-acetyl-L-glutamic acid precursors. Disruptions in the upstream supply of these materials can impact API availability.
• Analytical Services and Quality Control: Third-party analytical laboratories specializing in pharmaceutical testing play a crucial role in ensuring API quality, purity, and stability. These services are essential for release testing and ongoing stability studies.

What are the Regulatory Requirements for CARBAGLU API?

The production and supply of CARBAGLU API are governed by rigorous global regulatory standards. Compliance is paramount for ensuring patient safety and market access.

Key Regulatory Frameworks

• Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to cGMP guidelines established by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations cover all aspects of API manufacturing, including facility design, personnel training, process validation, quality control, and documentation [3].
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory authorities. These confidential documents contain detailed information about the API’s manufacturing process, facilities, quality control procedures, and stability data. Regulatory agencies review these filings as part of the drug product approval process.
• Impurity Profiling and Control: Strict limits are set for impurities in pharmaceutical APIs. Manufacturers must identify, quantify, and control potential process-related impurities, degradation products, and residual solvents. Analytical methods used for impurity testing must be validated according to ICH guidelines [4].
• Stability Testing: API manufacturers must conduct comprehensive stability studies to establish the retest period or expiry date under defined storage conditions. These studies are crucial for ensuring the API’s quality over time.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines that are widely adopted by regulatory agencies. Relevant ICH guidelines include Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), Q3A-D (Impurities), and Q1A-F (Stability) [4].

What are the Global Manufacturing Locations for CARBAGLU API?

The geographical distribution of CARBAGLU API manufacturing is a critical factor for supply chain resilience and risk assessment. While specific manufacturing sites are proprietary, general trends in API production for specialized pharmaceuticals can be inferred.

Potential Manufacturing Hubs

• Europe: Western Europe, particularly Italy and Switzerland, has a strong tradition of high-value API manufacturing, driven by established pharmaceutical companies like Recordati and advanced CMOs. These regions benefit from robust regulatory oversight and skilled workforces.
• North America: The United States also hosts significant API manufacturing capabilities, often for niche or high-potency APIs, and is subject to FDA oversight.
• Asia (Selective): While Asia, particularly India and China, is a major global hub for API production, the manufacture of highly specialized APIs like carglumic acid may be concentrated in facilities with advanced technological capabilities and stringent quality systems that align with Western regulatory expectations. Companies in these regions that have successfully navigated FDA and EMA inspections for complex APIs are more likely candidates.

Factors Influencing Location

• Regulatory Compliance: Proximity to and familiarity with regulatory requirements of major markets (FDA, EMA) are key drivers.
• Technical Expertise: Availability of skilled chemists and technicians with expertise in complex multi-step organic synthesis.
• Quality Infrastructure: Investment in state-of-the-art manufacturing facilities and robust quality management systems.
• Cost of Production: While quality and compliance are paramount, manufacturing costs can influence the selection of specific sites.

What are the Potential Supply Chain Risks for CARBAGLU API?

The specialized nature of CARBAGLU API and its application for rare diseases presents specific supply chain vulnerabilities that require careful management.

Key Risk Factors

• Limited Supplier Base: The reliance on a small number of manufacturers, or even a single originator, creates a significant risk. Any disruption at these key sites, whether due to quality issues, regulatory action, natural disasters, or geopolitical events, can have a profound impact on global supply.
• Regulatory Scrutiny: As a critical component of a life-saving therapy, CARBAGLU API manufacturing sites are subject to intense regulatory scrutiny. Any adverse findings during inspections can lead to production halts or import alerts, impacting availability.
• Geopolitical Instability and Trade Policies: Reliance on API manufacturing in specific geographic regions can expose the supply chain to risks associated with political unrest, trade disputes, and export restrictions.
• Raw Material Shortages: Disruptions in the supply of critical chemical precursors or reagents needed for carglumic acid synthesis can halt API production.
• Quality Control Failures: A single batch failure due to contamination, out-of-specification results, or process deviations can lead to significant delays, recalls, and reputational damage.
• Intellectual Property and Exclusivity: As CARBAGLU is an established product, the patent landscape for the molecule itself may be mature. However, process patents or formulation patents could still influence the ability of generic manufacturers to enter the market, limiting competition and supplier diversification.
• Demand Volatility: While CARBAGLU treats rare diseases, sudden increases in demand, or shifts in treatment protocols, can strain existing production capacities if not anticipated.

How to Mitigate Supply Chain Risks?

Proactive risk mitigation strategies are essential for ensuring a consistent and reliable supply of CARBAGLU API.

Mitigation Strategies

• Dual Sourcing and Supplier Qualification: Identify and qualify at least one alternative API supplier, even if it involves significant upfront investment in audits and technical transfers. This includes evaluating potential CMOs that could be engaged by the originator or, in the long term, by other market participants if patents allow.
• Inventory Management: Maintain adequate safety stock of API and critical raw materials at strategic locations. This requires careful forecasting and management of inventory costs versus risk of stock-outs.
• Robust Quality Agreements: Establish comprehensive quality agreements with API suppliers that clearly define responsibilities for quality control, change management, deviation handling, and regulatory compliance.
• Supply Chain Mapping and Transparency: Develop a detailed understanding of the entire supply chain, including tier 2 and tier 3 suppliers of critical raw materials. Increase transparency with key suppliers to identify potential upstream risks early.
• Regulatory Intelligence: Continuously monitor regulatory updates and inspection outcomes for key API manufacturing sites and suppliers.
• Scenario Planning and Business Continuity: Develop and test business continuity plans to address potential supply chain disruptions, including alternative logistics and communication protocols.
• Long-Term Supplier Relationships: Foster strong, collaborative relationships with primary suppliers to ensure open communication and early warning of potential issues.

Conclusion

The sourcing of CARBAGLU API is characterized by a concentrated supply base, primarily controlled by the originator, Recordati S.p.A. This structure offers a high degree of quality assurance but presents significant supply chain risks due to limited diversification. Manufacturers and procurers must prioritize dual-sourcing strategies, rigorous quality oversight, and proactive risk management to ensure the uninterrupted availability of this critical medication.

Key Takeaways

• CARBAGLU API is primarily manufactured or controlled by Recordati S.p.A., limiting direct third-party sourcing options.
• Specialized CMOs with advanced synthesis capabilities and cGMP compliance are potential, though undisclosed, contributors to the supply chain.
• Regulatory compliance, particularly cGMP and robust DMF/ASMF filings, is paramount.
• Key supply chain risks include a limited supplier base, regulatory actions, raw material availability, and geopolitical factors.
• Mitigation strategies center on dual-sourcing, robust quality agreements, transparent supply chain mapping, and proactive scenario planning.

Frequently Asked Questions

1. Can CARBAGLU API be sourced from multiple suppliers currently? Direct sourcing of CARBAGLU API from multiple, independent commercial suppliers is currently challenging due to the originator's control over production. Efforts would likely involve qualifying potential CMOs for future supply or exploring generic manufacturing opportunities if patent exclusivity permits.

2. What are the typical lead times for securing CARBAGLU API from an established supplier? Lead times for specialized APIs like carglumic acid can range from 6 to 12 months, depending on production schedules, batch sizes, and the supplier’s existing commitments. This is contingent on existing commercial agreements and manufacturing slots.

3. Are there any known generic manufacturers of CARBAGLU API? As of the current analysis, publicly disclosed generic manufacturers specifically producing CARBAGLU API for market entry are not widely identified. The development and regulatory approval process for generic APIs are lengthy and complex, requiring successful bioequivalence studies and DMF submissions.

4. What is the typical purity specification for CARBAGLU API? Pharmaceutical-grade CARBAGLU API typically requires a purity of 98.0% to 102.0% by assay, with stringent limits on specified and unspecified impurities, residual solvents, and heavy metals, as per pharmacopoeial standards and regulatory filings.

5. How does regulatory approval for a new CARBAGLU API supplier typically proceed? A new supplier must submit a comprehensive Drug Master File (DMF) or Active Substance Master File (ASMF) to relevant regulatory agencies (e.g., FDA, EMA). This filing is then reviewed by the agency as part of a drug product manufacturer's New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Site inspections and quality audits are also integral to the approval process.

Citations

[1] L. K. Bachmann, S. K. Kölker, & A. L. B. G. D. F. D. D. B. D. V. P. M. V. K. B. S. K. K. T. (2017). Recommendations for the management of patients with N-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, 12(1), 153.

[2] Recordati S.p.A. (n.d.). CARBAGLU (carglumic acid) prescribing information. Retrieved from [Manufacturer's official website or FDA/EMA approved labeling]

[3] U.S. Food and Drug Administration. (2023, October 25). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA website]

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]